Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 264

1.

Advantage of a Narrow Spectrum Host Defense (Antimicrobial) Peptide Over a Broad Spectrum Analog in Preclinical Drug Development.

Ostorhazi E, Hoffmann R, Herth N, Wade JD, Kraus CN, Otvos L Jr.

Front Chem. 2018 Aug 21;6:359. doi: 10.3389/fchem.2018.00359. eCollection 2018.

2.

Synergy Between Proline-Rich Antimicrobial Peptides and Small Molecule Antibiotics Against Selected Gram-Negative Pathogens in vitro and in vivo.

Otvos L Jr, Ostorhazi E, Szabo D, Zumbrun SD, Miller LL, Halasohoris SA, Desai PD, Int Veldt SM, Kraus CN.

Front Chem. 2018 Aug 14;6:309. doi: 10.3389/fchem.2018.00309. eCollection 2018.

3.

Racing on the Wrong Track.

Otvos L.

Front Chem. 2017 Jun 19;5:42. doi: 10.3389/fchem.2017.00042. eCollection 2017.

4.

Adiponectin is an endogenous anti-fibrotic mediator and therapeutic target.

Marangoni RG, Masui Y, Fang F, Korman B, Lord G, Lee J, Lakota K, Wei J, Scherer PE, Otvos L, Yamauchi T, Kubota N, Kadowaki T, Asano Y, Sato S, Tourtellotte WG, Varga J.

Sci Rep. 2017 Jun 30;7(1):4397. doi: 10.1038/s41598-017-04162-1.

5.

Transdermally administered proline-arginine-rich host defense peptides show systemic efficacy in a lethal mouse bacteremia model.

Ostorhazi E, Horvath A, Szabo D, Otvos L Jr.

Amino Acids. 2017 Sep;49(9):1647-1651. doi: 10.1007/s00726-017-2457-7. Epub 2017 Jun 29.

PMID:
28664267
6.

Host Defense Peptides and Cancer; Perspectives on Research Design and Outcomes.

Otvos L.

Protein Pept Lett. 2017;24(10):879-886. doi: 10.2174/0929866524666170202153501. Review.

PMID:
28155618
7.

The Effect of Selective D- or Nα-Methyl Arginine Substitution on the Activity of the Proline-Rich Antimicrobial Peptide, Chex1-Arg20.

Li W, Sun Z, O'Brien-Simpson NM, Otvos L, Reynolds EC, Hossain MA, Separovic F, Wade JD.

Front Chem. 2017 Jan 19;5:1. doi: 10.3389/fchem.2017.00001. eCollection 2017.

8.

Corrigendum: Designer Leptin Receptor Antagonist Allo-aca Inhibits VEGF Effects in Ophthalmic Neoangiogenesis Models.

Coroniti R, Farjo R, Nuno DJ, Otvos L, Scolaro L, Surmacz E.

Front Mol Biosci. 2016 Nov 18;3:75. eCollection 2016.

9.

C-Terminal Modification and Multimerization Increase the Efficacy of a Proline-Rich Antimicrobial Peptide.

Li W, O'Brien-Simpson NM, Yao S, Tailhades J, Reynolds EC, Dawson RM, Otvos L Jr, Hossain MA, Separovic F, Wade JD.

Chemistry. 2017 Jan 5;23(2):390-396. doi: 10.1002/chem.201604172. Epub 2016 Nov 16.

PMID:
27862429
10.

Designer Leptin Receptor Antagonist Allo-aca Inhibits VEGF Effects in Ophthalmic Neoangiogenesis Models.

Coroniti R, Fario R, Nuno DJ, Otvos L, Scolaro L, Surmacz E.

Front Mol Biosci. 2016 Oct 13;3:67. eCollection 2016. Erratum in: Front Mol Biosci. 2016 Nov 18;3:75.

11.

Immunomodulatory effects of anti-microbial peptides.

Otvos L Jr.

Acta Microbiol Immunol Hung. 2016 Sep;63(3):257-277. Epub 2016 Aug 19. Review.

PMID:
27539330
12.

Leptin Induces Hypertension and Endothelial Dysfunction via Aldosterone-Dependent Mechanisms in Obese Female Mice.

Huby AC, Otvos L Jr, Belin de Chantemèle EJ.

Hypertension. 2016 May;67(5):1020-8. doi: 10.1161/HYPERTENSIONAHA.115.06642. Epub 2016 Mar 7.

13.

Membrane interactions of proline-rich antimicrobial peptide, Chex1-Arg20, multimers.

Li W, Sani MA, Jamasbi E, Otvos L Jr, Hossain MA, Wade JD, Separovic F.

Biochim Biophys Acta. 2016 Jun;1858(6):1236-43. doi: 10.1016/j.bbamem.2016.02.035. Epub 2016 Feb 27.

14.

Multimerization of a Proline-Rich Antimicrobial Peptide, Chex-Arg20, Alters Its Mechanism of Interaction with the Escherichia coli Membrane.

Li W, O'Brien-Simpson NM, Tailhades J, Pantarat N, Dawson RM, Otvos L Jr, Reynolds EC, Separovic F, Hossain MA, Wade JD.

Chem Biol. 2015 Sep 17;22(9):1250-8. doi: 10.1016/j.chembiol.2015.08.011.

15.

Polyvinyl alcohol nanofiber formulation of the designer antimicrobial peptide APO sterilizes Acinetobacter baumannii-infected skin wounds in mice.

Sebe I, Ostorhazi E, Fekete A, Kovacs KN, Zelko R, Kovalszky I, Li W, Wade JD, Szabo D, Otvos L Jr.

Amino Acids. 2016 Jan;48(1):203-11. doi: 10.1007/s00726-015-2080-4. Epub 2015 Aug 29.

PMID:
26319645
16.

Reciprocal Inhibitory Interactions Between the Reward-Related Effects of Leptin and Cocaine.

You ZB, Wang B, Liu QR, Wu Y, Otvos L, Wise RA.

Neuropsychopharmacology. 2016 Mar;41(4):1024-33. doi: 10.1038/npp.2015.230. Epub 2015 Aug 5.

17.

The adipokine leptin mediates muscle- and liver-derived IGF-1 in aged mice.

Hamrick MW, Dukes A, Arounleut P, Davis C, Periyasamy-Thandavan S, Mork S, Herberg S, Johnson MH, Isales CM, Hill WD, Otvos L Jr, Belin de Chantemèle EJ.

Exp Gerontol. 2015 Oct;70:92-6. doi: 10.1016/j.exger.2015.07.014. Epub 2015 Jul 26.

18.

Commentary: drugs from bugs.

Otvos L.

Curr Protein Pept Sci. 2015;16(6):476-7. No abstract available.

PMID:
26138813
19.

Molecular targeting of obesity pathways in cancer.

Surmacz E, Otvos L.

Horm Mol Biol Clin Investig. 2015 May;22(2):53-62. doi: 10.1515/hmbci-2015-0007. Review.

PMID:
25879324
20.

Therapeutic utility of antibacterial peptides in wound healing.

Otvos L Jr, Ostorhazi E.

Expert Rev Anti Infect Ther. 2015 Jul;13(7):871-81. doi: 10.1586/14787210.2015.1033402. Epub 2015 Apr 3. Review.

PMID:
25835521
21.

Optimization of adiponectin-derived peptides for inhibition of cancer cell growth and signaling.

Otvos L Jr, Kovalszky I, Olah J, Coroniti R, Knappe D, Nollmann FI, Hoffmann R, Wade JD, Lovas S, Surmacz E.

Biopolymers. 2015 May;104(3):156-66. doi: 10.1002/bip.22627.

PMID:
25683126
22.

Development of second generation peptides modulating cellular adiponectin receptor responses.

Otvos L Jr, Knappe D, Hoffmann R, Kovalszky I, Olah J, Hewitson TD, Stawikowska R, Stawikowski M, Cudic P, Lin F, Wade JD, Surmacz E, Lovas S.

Front Chem. 2014 Oct 17;2:93. doi: 10.3389/fchem.2014.00093. eCollection 2014.

23.

Current challenges in peptide-based drug discovery.

Otvos L Jr, Wade JD.

Front Chem. 2014 Aug 8;2:62. doi: 10.3389/fchem.2014.00062. eCollection 2014. No abstract available.

24.

Proline-rich antimicrobial peptides: potential therapeutics against antibiotic-resistant bacteria.

Li W, Tailhades J, O'Brien-Simpson NM, Separovic F, Otvos L Jr, Hossain MA, Wade JD.

Amino Acids. 2014 Oct;46(10):2287-94. doi: 10.1007/s00726-014-1820-1. Epub 2014 Aug 21. Review.

PMID:
25141976
25.

Designer adiponectin receptor agonist stabilizes metabolic function and prevents brain injury caused by HIV protease inhibitors.

Pepping JK, Otvos L Jr, Surmacz E, Gupta S, Keller JN, Bruce-Keller AJ.

J Neuroimmune Pharmacol. 2014 Jun;9(3):388-98. doi: 10.1007/s11481-014-9529-1. Epub 2014 Feb 23.

26.

The designer leptin antagonist peptide Allo-aca compensates for short serum half-life with very tight binding to the receptor.

Otvos L Jr, Vetter SW, Koladia M, Knappe D, Schmidt R, Ostorhazi E, Kovalszky I, Bionda N, Cudic P, Surmacz E, Wade JD, Hoffmann R.

Amino Acids. 2014 Apr;46(4):873-82. doi: 10.1007/s00726-013-1650-6. Epub 2013 Dec 24.

PMID:
24366600
27.

Killer bee molecules: antimicrobial peptides as effector molecules to target sporogonic stages of Plasmodium.

Carter V, Underhill A, Baber I, Sylla L, Baby M, Larget-Thiery I, Zettor A, Bourgouin C, Langel U, Faye I, Otvos L, Wade JD, Coulibaly MB, Traore SF, Tripet F, Eggleston P, Hurd H.

PLoS Pathog. 2013;9(11):e1003790. doi: 10.1371/journal.ppat.1003790. Epub 2013 Nov 21.

28.

IMAP 2012: Antimicrobial peptides to combat (multi)drug-resistant pathogens.

Adermann K, Hoffmann R, Otvos L.

Protein Pept Lett. 2014 Apr;21(4):319-20. No abstract available.

PMID:
24164271
29.

Hydroxyproline substitutions stabilize non-glycosylated drosocin against serum proteases without challenging its antibacterial activity.

Knappe D, Cassone M, Nollmann FI, Otvos L, Hoffmann R.

Protein Pept Lett. 2014 Apr;21(4):321-9.

PMID:
24164265
30.

The designer proline-rich antibacterial peptide A3-APO prevents Bacillus anthracis mortality by deactivating bacterial toxins.

Otvos L Jr, Flick-Smith H, Fox M, Ostorhazi E, Dawson RM, Wade JD.

Protein Pept Lett. 2014 Apr;21(4):374-81.

PMID:
24164262
31.

Exploring leptin antagonism in ophthalmic cell models.

Scolaro L, Parrino C, Coroniti R, Otvos L Jr, Surmacz E.

PLoS One. 2013 Oct 3;8(10):e76437. doi: 10.1371/journal.pone.0076437. eCollection 2013.

32.

Rapid systemic and local treatments with the antibacterial peptide dimer A3-APO and its monomeric metabolite eliminate bacteria and reduce inflammation in intradermal lesions infected with Propionibacterium acnes and meticillin-resistant Staphylococcus aureus.

Ostorhazi E, Voros E, Nemes-Nikodem E, Pinter D, Sillo P, Mayer B, Wade JD, Otvos L Jr.

Int J Antimicrob Agents. 2013 Dec;42(6):537-43. doi: 10.1016/j.ijantimicag.2013.08.001. Epub 2013 Sep 7.

PMID:
24074727
33.

Identification of adipokine receptor agonists and turning them to antagonists.

Otvos L Jr.

Methods Mol Biol. 2013;1081:195-209. doi: 10.1007/978-1-62703-652-8_12.

PMID:
24014441
34.

Designer peptide antagonist of the leptin receptor with peripheral antineoplastic activity.

Beccari S, Kovalszky I, Wade JD, Otvos L Jr, Surmacz E.

Peptides. 2013 Jun;44:127-34. doi: 10.1016/j.peptides.2013.03.027. Epub 2013 Apr 6.

PMID:
23567149
35.

Leptin and ghrelin prevent hippocampal dysfunction induced by Aβ oligomers.

Martins I, Gomes S, Costa RO, Otvos L, Oliveira CR, Resende R, Pereira CM.

Neuroscience. 2013 Jun 25;241:41-51. doi: 10.1016/j.neuroscience.2013.02.062. Epub 2013 Mar 16.

PMID:
23506735
36.

Vaccination with M2e-based multiple antigenic peptides: characterization of the B cell response and protection efficacy in inbred and outbred mice.

Wolf AI, Mozdzanowska K, Williams KL, Singer D, Richter M, Hoffmann R, Caton AJ, Otvos L, Erikson J.

PLoS One. 2011;6(12):e28445. doi: 10.1371/journal.pone.0028445. Epub 2011 Dec 13.

37.

Design and development of a peptide-based adiponectin receptor agonist for cancer treatment.

Otvos L Jr, Haspinger E, La Russa F, Maspero F, Graziano P, Kovalszky I, Lovas S, Nama K, Hoffmann R, Knappe D, Cassone M, Wade J, Surmacz E.

BMC Biotechnol. 2011 Oct 5;11:90. doi: 10.1186/1472-6750-11-90.

38.

Targeting the leptin receptor: a potential new mode of treatment for breast cancer.

Otvos L Jr, Surmacz E.

Expert Rev Anticancer Ther. 2011 Aug;11(8):1147-50. doi: 10.1586/era.11.109. No abstract available.

PMID:
21916566
39.

Glioblastoma-derived leptin induces tube formation and growth of endothelial cells: comparison with VEGF effects.

Ferla R, Bonomi M, Otvos L Jr, Surmacz E.

BMC Cancer. 2011 Jul 19;11:303. doi: 10.1186/1471-2407-11-303.

40.

Toward understanding the role of leptin and leptin receptor antagonism in preclinical models of rheumatoid arthritis.

Otvos L Jr, Shao WH, Vanniasinghe AS, Amon MA, Holub MC, Kovalszky I, Wade JD, Doll M, Cohen PL, Manolios N, Surmacz E.

Peptides. 2011 Aug;32(8):1567-74. doi: 10.1016/j.peptides.2011.06.015. Epub 2011 Jun 23.

PMID:
21723351
41.

Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer.

Otvos L Jr, Kovalszky I, Riolfi M, Ferla R, Olah J, Sztodola A, Nama K, Molino A, Piubello Q, Wade JD, Surmacz E.

Eur J Cancer. 2011 Jul;47(10):1578-84. doi: 10.1016/j.ejca.2011.01.018. Epub 2011 Feb 23.

PMID:
21353530
42.

Broad-spectrum antimicrobial efficacy of peptide A3-APO in mouse models of multidrug-resistant wound and lung infections cannot be explained by in vitro activity against the pathogens involved.

Ostorhazi E, Holub MC, Rozgonyi F, Harmos F, Cassone M, Wade JD, Otvos L Jr.

Int J Antimicrob Agents. 2011 May;37(5):480-4. doi: 10.1016/j.ijantimicag.2011.01.003. Epub 2011 Feb 24.

PMID:
21353493
43.

Leptin-based therapeutics.

Scolaro L, Cassone M, Kolaczynski JW, Otvos L Jr, Surmacz E.

Expert Rev Endocrinol Metab. 2010 Nov;5(6):875-889. doi: 10.1586/eem.10.61.

PMID:
30780830
44.

Preclinical advantages of intramuscularly administered peptide A3-APO over existing therapies in Acinetobacter baumannii wound infections.

Ostorhazi E, Rozgonyi F, Sztodola A, Harmos F, Kovalszky I, Szabo D, Knappe D, Hoffmann R, Cassone M, Wade JD, Bonomo RA, Otvos L Jr.

J Antimicrob Chemother. 2010 Nov;65(11):2416-22. doi: 10.1093/jac/dkq337. Epub 2010 Sep 1.

45.

Intramuscularly administered peptide A3-APO is effective against carbapenem-resistant Acinetobacter baumannii in mouse models of systemic infections.

Ostorhazi E, Rozgonyi F, Szabo D, Binas A, Cassone M, Wade JD, Nolte O, Bethel CR, Bonomo RA, Otvos L Jr.

Biopolymers. 2011;96(2):126-9. doi: 10.1002/bip.21443.

46.

Peptide-based leptin receptor antagonists for cancer treatment and appetite regulation.

Otvos L Jr, Kovalszky I, Scolaro L, Sztodola A, Olah J, Cassone M, Knappe D, Hoffmann R, Lovas S, Hatfield MP, Beko G, Zhang S, Wade JD, Surmacz E.

Biopolymers. 2011;96(2):117-25. doi: 10.1002/bip.21377.

PMID:
20564005
47.

Synergy among antibacterial peptides and between peptides and small-molecule antibiotics.

Cassone M, Otvos L Jr.

Expert Rev Anti Infect Ther. 2010 Jun;8(6):703-16. doi: 10.1586/eri.10.38. Review.

PMID:
20521897
48.

Leptin-based glycopeptide induces weight loss and simultaneously restores fertility in animal models.

Kovalszky I, Surmacz E, Scolaro L, Cassone M, Ferla R, Sztodola A, Olah J, Hatfield MP, Lovas S, Otvos L Jr.

Diabetes Obes Metab. 2010 May;12(5):393-402. doi: 10.1111/j.1463-1326.2009.01170.x.

PMID:
20415687
49.

The designer proline-rich antibacterial peptide A3-APO is effective against systemic Escherichia coli infections in different mouse models.

Szabo D, Ostorhazi E, Binas A, Rozgonyi F, Kocsis B, Cassone M, Wade JD, Nolte O, Otvos L Jr.

Int J Antimicrob Agents. 2010 Apr;35(4):357-61. doi: 10.1016/j.ijantimicag.2009.10.015. Epub 2009 Dec 23.

PMID:
20031377
50.

The antibacterial effect of a proline-rich antibacterial peptide A3-APO.

Rozgonyi F, Szabo D, Kocsis B, Ostorházi E, Abbadessa G, Cassone M, Wade JD, Otvos L Jr.

Curr Med Chem. 2009;16(30):3996-4002. Review.

PMID:
19747127

Supplemental Content

Support Center